1Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5, Haiyuncang, Dongcheng District, Beijing 100700, China 2First Clinical Medical School, Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang District,

Beijing 100029, China Correspondence should be addressed to Shengxian Wu; [email protected] Received 10 May 2021; Revised 10 November 2021; Accepted 25 November 2021; Published 9 December 2021 Academic Editor: Khalid Rahman

Copyright © 2021 Shuang Zhao et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Ginkgo biloba leaf preparations (GLPs) are widely used in ischemic stroke, and uncertainty remains regarding their clinical efficacy. To evaluate systematically the clinical efficacy and safety of GLPs in the treatment of ischemic stroke, we examine evidence from randomized controlled trials (RCTs). Methods. We examine studies published prior to November 2021 that were found from searching the following sources: PubMed, China National Knowledge Infrastructure (CNKI), WANFANG DATA, Chongqing VIP (CQVIP) databases, and Chinese Biomedical Literature (CBM). We evaluated the quality of the included references according to the Cochrane Manual of Systematic Evaluation and Meta-analysis (MA) performed using RevMan 5.2 software. Results. We included a total of 13 RCTs with clinical therapeutic effects, the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), hemorheology index, and adverse reaction index as evaluation criteria. ere were 631 cases in the observation group and 629 cases in the control group. MA results showed the following: NIHSS WMD −3.89, 95% CI: [−4.22, −3.56], I2 19%, P< 0.00001. is index is often used with nerve injury and can also be used to judge the recovery of nerve function. A lower score means less nerve damage and a better chance of recovery. e BI results were WMD 11.30, 95% CI: [9.83, 12.77], I2 7%, P< 0.00001. is index was used to assess patients’ ability to take care of themselves, with a higher score indicating a stronger ability to live independently. Clinical effective rate results were WMD 3.79, 95% CI: [2.49, 5.78], I2 0%, P< 0.00001, and this measure can be used to evaluate the effect of treatment clearly and objectively. Hemorheological index results show that plasma viscosity has WMD −0.16, 95% CI: [−0.20, −0.12], I2 40%, P< 0.00001 and fibrinogen (FIB) has WMD −1.13, 95% CI: [−1.23, −1.04], I2 0%, P< 0.00001. Plasma viscosity is mainly related to the amount of fibrinogen, and fibrinogen degradation is an important function of the fibrinolytic system. e imbalance of the fibrinolytic system plays an important role in the pathogenesis of cerebral infarction. Fibrinogen is a risk factor of ischemic cerebrovascular disease. Studies have shown that the infarct size of patients with secondary cerebral infarction after CEREBRAL infarction is correlated with their FIB level. In addition, FIB elevation is also one of the risk factors for early infarction after thrombolysis. erefore, FIB can be used as a detection index for the prevention of cerebral infarction recurrence adverse reactions. Our MA results for FIB show WMD 0.81, 95% CI: [0.38, 1.73], I2 0%, P 0.58, and RR < 1. Conclusion. e existing clinical evidence shows that GLP has a good therapeutic effect on patients with ischemic stroke and can improve their hemorheology indices. In addition, GLP is shown to be relatively safe.

Cerebrovascular disease is one of the leading causes of death in China, where it is estimated that there are 13 million

stroke patients [1]. Among the existing types of cerebrovascular diseases in China, about 70% of the patients suffer from ischemic stroke [2]. Ischemic stroke is characterized by a high mortality rate, a high teratogenicity rate, and a high

recurrence rate. It not only seriously affects the quality of life of patients but can also cause a serious economic burden on those afflicted and their families [3].

In recent years, a number of studies have provided evidence that Ginkgo biloba leaf extract has natural antioxidant properties, can specifically scavenge a variety of oxygen free radicals, can help activate antagonistic platelet activation factor and other biological activities, can significantly expand the cerebrovascular system, and can improve the symptoms of cerebral hypoxia [4–6]. e active ingredient in Ginkgo biloba ginkgolide has been shown to have a variety of neuroprotective and reparative effects that can help maintain the blood-brain barrier; reduce brain edema; improve energy metabolism; help with antioxidation, antiinflammation, and antiapoptosis; promote angiogenesis; and provide a therapeutic effect for ischemic stroke [7].

However, the clinical use of Ginkgo biloba is not just limited to the basic leaves. Leaf preparations can also include ginkgo ketone ester dripping pills, ginkgo ketone ester dispersing tablets, Shuxuening injections, ginkgo diterpene lactone glutamine injections, ginkgo lactone injections, and ginkgo damo. With the wider application of GLPs across the globe, reports of adverse events have been gradually increasing as well; the most common adverse events are allergic reactions and abnormal bleeding [8, 9].

Ginkgo acid, in particular, which is a toxic substance in Ginkgo biloba leaves, has been shown to be a major cause of such allergies [10]. In addition, the ginkgo substance ginkgolide is a natural platelet antagonist with antiplatelet effects [11], and this may increase bleeding when used in combination with anticoagulants. It is not yet clear whether the adverse reactions of Ginkgo biloba preparations are individual or common.

In this paper, we searched RCTs of GLP in the treatment of ischemic stroke that were published since the establishment of each of our databases in order to evaluate the clinical efficacy and safety of GLP in the treatment of ischemic stroke and to provide a reference for the clinical treatment of ischemic stroke.

We performed our MA according to the Cochrane Handbook for Systematic Reviews of Interventions [12] and presented our results based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [13].

1. 2.1. Literature Search. Two researchers (Shuang Zhao and Run-lei Zhang) searched PubMed, CNKI, WANFANG DATA, CQVIP, and CBM databases from their respective inception dates to November 2021. e search terms used were (in pseudo-logic): (stroke OR cerebral infarction OR ischemic stroke) AND (ginkgo OR Ginkgo biloba OR ginkgo biloba leaf preparation) AND (randomized controlled trial).
2. 2.2. Inclusion and Exclusion Criteria. We abided by the participants, interventions, comparisons, outcomes and study design (PICOS) approach in establishing our inclusion

criteria, which were as follows: (1) patients must have met the accepted diagnostic criteria for stroke with no restrictions on gender, age, BMI, or other measures. (2) We compared GLP with other interventions, and the possible comparisons were GLP plus conventional treatments versus conventional treatments. (3) We only included studies that reported at least one of the following outcomes: NIHSS, clinical therapeutic effect, BI, adverse reactions, plasma viscosity level, or fibrinogen.

e exclusion criteria were as follows: (1) review, experience, case reports, case reports, conference reports, animal experiments, and other literature; (2) duplicate publications, duplicate data, or incomplete literature; (3) intervention measures for other traditional Chinese medicine, Chinese patent medicine, acupuncture and massage, and other traditional Chinese medicine treatment literature; and (4) the observation group or control group had fewer than 20 cases or the total number was less than 40 cases.

No language restriction was applied.

1. 2.3. Study Selection. Our reviewers worked in pairs. ey first identified the articles that met the inclusion criteria through the title and abstract and then independently verified this through the full text.
2. 2.4. Data Collection Process. Two researchers (Pei-lin Chen and Rong Ren) independently extracted the following information using predesigned forms: lead author, publication year, details of intervention measurement, sample size, ages of the participants, outcomes, and adverse events. In cases of disagreement between two reviewers from a pair, a third author or group discussion decided on inclusion or exclusion.
3. 2.5. Risk of Bias Assessment. e methodological quality of the included studies was assessed by two researchers (Ya-wei Du and Sheng-xian Wu) according to the Cochrane handbook 5.1.0 [12]. Bias risk assessment was conducted from 7 items: random sequence generation, allocation concealment, blinding of researchers and subjects, blinded evaluation of study outcomes, integrity of outcome data, selective reporting of study results, and other biases. Green, yellow, and red colors with “+,” “−,” and “?” symbols denote “low risk bias,” “high risk bias,” and “unclear,” respectively, and the included literature was evaluated one by one. Disagreements were resolved through discussion with a third researcher (Hong Zheng).
4. 2.6. Statistical Analysis. We used RevMan 5.2 software to process and analyze our extracted data. Dichotomous data were analyzed using risk ratios (RRs) and continuous variables using mean differences (MDs) with 95% confidence intervals (CIs). e I2 statistic was used to evaluate the heterogeneity among studies. If I2<50% and P ≥0.1, then heterogeneity was small, and we chose the fixed-effect model for analysis. If I2> is 50% or P≤0.1, then heterogeneity was large, and we chose the random-effects model to analyze the

causes of heterogeneity. Subgroup analysis or sensitivity analysis was performed if necessary. We also elect that a Pstatistic less than 0.05 indicates statistically significant results. When more than 10 articles were included in an outcome index, funnel plots were used to determine whether there was publication bias.

1. 3.1. Literature Selection. A total of 630 published articles were retrieved, including 210 from WANFANG DATA, 198 from CNKI, 200 from CQVIP, and 22 from Pubmed, imported into NoteExpress literature management software, and then removed 350 duplicate references. We also excluded 70 articles, including academic papers, nonclinical randomized controlled trials, academic conferences, reviews, empirical medical cases, and knowledge lectures. In addition, we eliminated 120 irrelevant and unusable articles on interventions after reading the article titles and abstracts. After excluding studies with fewer than 20 participants in the control or treatment group, or 40 total participants, and excluding 77 articles that had the same author and the same type of research, 13 RCTs remained to be included in our MA. e screening process is shown in Figure 1.

1. 3.2. Characteristics of the Included Studies. A total of 13 articles meeting our criteria were included in the study, totaling 631 cases in the observation groups and 629 cases in the control groups. e included evaluation indices were clinical therapeutic effect in 9 articles, NIHSS in 7 articles, BI score in 5 articles, plasma viscosity level comparison in 6 articles, fibrinogen comparison in 4 articles, and the occurrence of adverse reactions in 5 articles (see Table 1).
2. 3.3. Risk of Bias Assessment. All 13 articles randomly assigned patients to the observation group or the control group. Specifically, of the 8 articles that used the random number method (low risk of bias), two articles did not mention the specific random method (unclear risk), and 3 of them may have adopted an inappropriate random method (high risk). None of the 13 studies described allocation concealment, double-blindness among participants, or blinding of outcome assessment (unclear risk).
3. 3.4. NIHSS. A total of 7 articles [14, 15, 19, 20, 22, 24, 26] used NIHSS as an evaluation index. Due to the presence of clinical heterogeneity in the index, we adopted a randomeffects model for combined analysis, and the total combined results are as follows: WMD −3.89, 95% CI: [−4.22, −3.56], I2 19%, and P<0.00001. e difference of NIHSS between the observation groups and the control groups is statistically significant, and the heterogeneity was small. is indicates

1. that the use of GLP may better improve the NIHSS, as shown in Figure 3.
2. 3.5. Clinical erapeutic Effect Evaluation. A total of 9 articles [14, 15, 19, 20, 22–26] used the clinical therapeutic effect as an evaluation index. Again, due to the presence of clinical heterogeneity in this index, we adopted a randomeffects model for combined analysis, and the total combined results are as follows: WMD 3.79, 95% CI: [2.49, 5.78], I2 0%, and P <0.00001. e difference of clinical therapeutic effect between the observation group and the control group was statistically significant, and the heterogeneity was small. is suggests that the combined use of GLP can achieve better clinical efficacy, as shown in Figure 4.
3. 3.6.BarthelIndex. A total of 5 articles [15, 23–26] used BI as an evaluation index. Once again, due to the presence of clinical heterogeneity in this index, we adopted a randomeffects model for combined analysis, and the total combined results are as follows: WMD 11.30, 95% CI: [9.83, 12.77], I2 7%, and P <0.00001. e difference of BI between the observation group and the control group was statistically significant, and the heterogeneity was small, again indicating that the use of GLP can improve the BI and improve living ability, as shown in Figure 5.
4. 3.7. Plasma Viscosity Comparison. A total of 6 articles
5. 3.9. Adverse Reactions Comparison. A total of 5 articles [17, 18, 23, 24, 26] used the comparison of adverse reactions as an evaluation index. Again, due to the presence of clinical heterogeneity in this index, we adopted a random-effects model for combined analysis, and the total combined results are as follows: WMD 0.81, 95% CI: [0.38, 1.73], I2 0%,

Pubmed:22, CNKI:198, WANFANG:210, CQVIP:200. (n=630)

Eliminating 350 duplicates. (n=280)

Eliminate 70 records: academic dissertation, nonrandomized trials, academic conference, review, experience medical case, knowledge lecture. (n=210)

Read the title and the abstract, 120 records excluded for no useable data and the Interventions were not relevant. (n=90)

Full-text articles assessed for eligibility, 77 records excluded for less than 20 cases from observation or control, the same author and the same study type, failure to meet inclusion criteria and different data indicators. (n=13)

13 RCTs met eligibility criteria, included in current meta-analysis

Figure 1: Flow diagram of the literature screening process and results.

and P 0.58, RR< 1. e difference of adverse reactions between the observation group and the control group was statistically significant, and the heterogeneity was small. is indicates that the number of ADR in the observation group is less than that in the control group, suggesting that the combined use of GLP and other interventions did not increase, at least at the same time, and may even have reduced the occurrence of ADR, as shown in Figure 8.

aspirin. Other clinical studies also show that sometimes combined use is not effective. In addition, a higher dose of aspirin can increase the risk of bleeding, and clopidogrel is not widely accepted due to its high price. Studies [33, 34] have shown that aspirin combined with GLP can reduce aspirin resistance under a regime of low-dose aspirin and can help to avoid adverse reactions from high-dose aspirin at the same time. Moreover, GLP has a high cost-potency ratio. erefore, while aspirin is the preferred drug for the secondary prevention of stroke, GLP can be used as a complementary therapy.

Ginkgo biloba is a deciduous perennial tree of the genus Ginkgo and the family Ginkgoaceae. Although once far more widespread than today, its leaves, kernels, and outer seed skins contain medicinal ingredients, and it is referred to in China as the “living fossil with treasure all over the body.” Ginkgo has been used as medicine for more than 600 years, and its efficacy was first recorded in “Shennong Ben Cao Jing.” Historically, China realized the medicinal value of ginkgo very early on. Li Shizhen in the Ming Dynasty wrote in his Compendium of Materia Medica that “Ginkgo enters the lung meridian, improves lung qi, eases asthma and reduces bowel movements.”

e treatment of ischemic stroke can have different effects according to different times of intervention. Studies [27, 28] have shown that treatment in the early stage of stroke is of great significance to the recovery effect and the prevention of the recurrence of stroke. Zhu et al. [29] studied the effect of intensivemedicaltreatmentonacuteischemicstroke. eyfound that, in addition to controlling blood pressure, blood lipid, blood glucose, and other indicators and guiding patients to improve their poor lifestyle, an intensive medical treatment plan was studied. eir drug treatment scheme was as follows: Patients first received a dose of aspirin of 100∼300mg/d, atorvastatin calcium 60∼80mg/d, and clopidogrel 300mg/d. After that, the dosage of aspirin was reduced to 100mg/d, atorvastatin calcium remained at 60∼80mg/d, and clopidogrel was adjusted to 75mg/d, which continued for 90 days. eir findings suggest that intensive medical treatment during the acute phase of stroke can promote the recovery of neurological function in patients but does not increase the risk of adverse outcomes. Aspirin is now recognized as an effective means to prevent recurrent stroke [30]. However, other clinical studies report that, for patients with aspirin resistance [31, 32], clopidogrel is usually used instead of or in combination with

Modern research on ginkgo began in the 1950s. German scientist Dr. Willmar Schwabe found an optimal composition ratio in Ginkgo biloba extract (GBE) to maximize the medicinal value of Ginkgo biloba leaves. e resulting standard product is called EGb761. Chinese medicine practitioners believe that Ginkgo biloba leaves have the effect of activating blood and nourishing the heart, astringing the lungs, and restraining the intestine [35]. e seed kernels have been found to moisten the lungs, relieve asthma, relieve cough, diuresis, stop white turbidity, kill insects, and reduce the symptoms of hangover, among other effects.

1: Details from trials.Table

2021 ±±Ginkgo biloba[26]Rt-PA +extract injectionRt-PA303056.285.0956.915.381 weeka, b, c, e, f

DurationOutcome

2018 ±±[19]Routine+rosiglitazone+ginkgo ester dispersive tabletsRoutine+rosiglitazone515153.6410.2553.7210.384 weeksa, b, d, e

DN, 2020 ±±[24]Routine+butylphthalide+ginkgolide injectionRoutine+butylphthalide393961.987.6561.827.514 weeksa, b, c, f

injection ±±Routine+Butylphthalide injection636365.137.2964.236.182 weeksb, c, d,

2016 ±±[15]Routine+shuxueningRoutine636368.38.567.17.92 weeksa, b, c

2012 [14]Aspirin+ozagrel+Ginkgo dameerAspirin+ozagrel404066.564.82 weeksa, b

2017 ±±[16]Routine+aspirin+ginkgo ester dispersive tabletsRoutine+aspirin414169.427.2468.728.142 weeksd, e

2019 ±±[20]Rt-PA+ginkgolide injectionRt-PA444363.087.1862.977.252 weeksa, b

2020 ±[22]Butylphthalide+ginkgo diterpene lactone glutamineButylphthalide414162.156.4561.376.442 weeksa, b

2020 ±±[21]Mannitol+aspirin+mecobalamin+ginkgo ester dropping pillsMannitol+aspirin+mecobalamin505053.1010.3952.3910.232 weeksd, e

bilobaleaf extract ±±Edaravone+propranolol+aspirin+mannitol+furosemide737359.4813.2458.9113.074 weeksd, f

2017 ±[18]Routine+alprostadil+ginkgo ester dispersive tabletsRoutine+alprostadil494968.9+1.768.21.62 weeksd, f

2020 ±[23]Routine+ginkgolide injectionRoutine treatment464668.9+1.768.21.62 weeksd, f

TreatmentControlTreatmentControlTreatmentControl

no. InterventionSample sizeAge

Outcomes: (a) NIHSS; (b) clinical therapeutic effect; (c) BI; (d) plasma viscosity; (e) fibrinogen; (f) adverse reactions.

Ginkgo bilobaRoutine+Butylphthalide injection+diterpene lactone

GinkgoEdaravone+propranolol+aspirin+mannitol+furosemide+

year Reference

2021 [25]

2017 [17]

Wang LM,

Zhang TT,

Zhou QW,

Zhou YF,

Zhou G,

Chen E,

Yang T,

Xiao H,

Shi YF,

author,

Shi XJ,

Sun T,

Wu Y,

Zhang

First

Blinding of participants and personnel (performance bias)

Blinding of outcome assessment (detection bias)

Random sequence generation (selection bias)

Incomplete outcome data (attrition bias)

Allocation concealment (selection bias)

Selective reporting (reporting bias)

Other bias

Sun T 2012

Zhou YF 2016

Shi YF 2017 Wang LM 2017

Yang T 2017

Zhou G 2018 Zhou QW 2019

Chen E 2020 Zhang DN 2020

Wu Y 2020 Xiao H 2020

Shi XJ 2021 Zhang TT 2021

Figure 2: Risk of bias assessment for the 13 included studies.

Weight (%)

Mean Difference IV, Random, 95% CI IV, Random, 95% CI

Experimental Control Mean Difference

Study or Subgroup Sun T 2012 Zhou YF 2016 Zhou G 2018 Zhou QW 2019 Zhang DN 2020 Xiao H 2020 Zhang TT 2021 Total (95% CI)

Year

Total

SD

Mean

Total

SD

Mean

2012 2016

1. -4.18 [-5.05, -3.31]
2. -3.80 [-4.39, -3.21]
3. -2.85 [-4.13, -1.57]
4. -5.01 [-6.12, -3.90]
5. -3.75 [-4.15, -3.35]
6. -3.91 [-5.10, -2.72]
7. -4.01 [-4.97, -3.05]
8. -3.89 [-4.22, -3.56]

11.8 22.0 6.0 7.8 35.3 6.9 10.1

1. 40 63 51 43 39
2. 41 30

2.47 2.2 3.41 2.73 1.08 3.17 2.31

7.83 13 16.59 15.68 9.16 12.4 12.35

1. 40 63 51 44 39
2. 41 30

1.36 0.9 3.18 2.56 0.67 2.23 1.36

3.65 9.2 13.74 10.67 5.41 8.49 8.34

1. 2018
2. 2019
3. 2020

1. 2020
2. 2021

100.0

307

308

Heterogeneity: Tau2 = 0.04; Chi2 = 7.44, df = 6 (P = 0.28); I2 = 19% Test for overall effect: Z = 23.25 (P < 0.00001)

-100 Favours [experimental] Favours [control]

-50 0 50 100

Figure 3: Forest plot of NIHSS analysis.

According to current studies, the main active ingredients of Ginkgo biloba leaves are ginkgo flavonoids and Ginkgo biloba terpene lactone, both of which can improve blood flow and inhibit platelet aggregation [36]. A large number of

experiments have also shown that Ginkgo biloba leaf extract can scavenge free radicals, protect neuronal cell membranes, and inhibit cell apoptosis induced by free radicals [37]. Ginkgo biloba leaf is widely used in the treatment of the

Weight (%) 9.7 10.0 14.2 15.6

Experimental Control Odds Ratio Odds Ratio M-H, Random, 95% CI

Study or Subgroup

Total

Total

Events

M-H, Random, 95% CI

Year 2012 2016

Events

1. 40 63 51 43
2. 41

1. 40 63 51 44
2. 41

1. 27 52 38
2. 28

5.94 [1.54, 22.90] 4.23 [1.12, 15.99] 3.15 [1.03, 9.62] 3.39 [1.17, 9.84]

Sun T 2012 Zhou YF 2016 Zhou G 2018 Zhou QW 2019

1. 37 60 46
2. 38

1. 2018
2. 2019
3. 2020
4. 2021

37

46

43

46

9.3

3.49 [0.88, 13.84]

2020

Wu Y 2020

30 20 48

11.5 8.9 17.0 100.0

1. 3.39 [0.98, 11.74]
2. 4.50 [1.09, 18.50]

Zhang DN 2020 Xiao H 2020 Zhang TT 2021 Shi XJ 2021

37 27 57

31

3.9

9.81 [1.16, 82.71]

38

30 63

30 63

1. 2.97 [1.07, 8.25]
2. 3.79 [2.49, 5.78]

416

417

Total (95% CI) Total events Heterogeneity: Tau2 = 0.00; Chi2 = 1.69, df = 8 (P = 0.99); I2 = 0% Test for overall effect: Z = 6.21 (P < 0.00001)

311

383

0.01 0.1 1 10 100

Favours [control] Favours [experimental]

Figure 4: Forest diagram of clinical therapeutic effect.

Favours [experimental] Control Mean Difference IV, Random, 95% CI

Weight (%) 20.6 17.3 36.8 8.2 17.2 100.0

Mean Difference IV, Random, 95% CI

Study or Subgroup

Mean 71 74.12 84.51 65.48 83.54

SD 9.4 8.58 5.28 16.24 7.12

Mean

SD 8.4 8.14 4.84 12.49 6.4

Total

Total

Year 2016

Zhou YF 2016 Wu Y 2020 Zhang DN 2020 Shi XJ 2021 Zhang TT 2021

61.2 63.2 73.92 51.63 69.76

63 46 39 63 30

63 46 39 63 30

1. 9.80 [6.69, 12.91]
2. 10.92 [7.50, 14.34]

1. 2020
2. 2021

1. 10.59 [8.34, 12.84] 13.85 [8.79, 18.91]
2. 11.30 [9.83, 12.77]

241

Total (95% CI) 241 Heterogeneity: Tau2 = 0.21; Chi2 = 4.31, df = 4 (P = 0.37); I2 = 7% Test for overall effect: Z = 15.08 (P < 0.00001)

-100 Favours [control] Favours [experimental]

-50 0 50 100

Figure 5: Forest plot of BI analysis.

Mean Difference IV, Random, 95% CI

Weight (%) 0.3 35.6 16.2 21.3 0.7 25.8 100.0

Experimental Control Mean Difference IV, Random, 95% CI

Study or Subgroup

Year 2017 2017

Total

SD

Mean

Total

SD 1.15 0.1 0.22 0.17 1.22 0.14

Mean

1. -0.64 [-1.39, 0.11]
2. -0.16 [-0.20, -0.12]
3. -0.11 [-0.20, -0.02]
4. -0.16 [-0.23, -0.09]
5. -0.73 [-1.23, -0.23]
6. -0.18 [-0.24, -0.12]
7. -0.16 [-0.20, -0.12]

21 73

1.32 0.12 0.21 0.18 1.32 0.18

6.02 1.65 1.79 1.35 6.12 1.39

21 73

5.38 1.49 1.68 1.19 5.39 1.21

Shi YF 2017 Wang LM 2017 Yang T 2017 Zhou G 2018 Chen E 2020 Shi XJ 2021

1. 2017
2. 2018

1. 49 51
2. 50 63

1. 49 51
2. 50 63

1. 2020
2. 2021

Total (95% CI) Heterogeneity: Tau2 = 0.00; Chi2 = 8.40, df = 5 (P = 0.14); I2 = 40% Test for overall effect: Z = 7.58 (P < 0.00001)

307

307

-100 Favours [experimental] Favours [control]

-50 0 50 100

Figure 6: Forest plot of plasma viscosity.

Mean Difference IV, Random, 95% CI IV, Random, 95% CI Year

Weight (%)

Experimental Control Mean Difference

Study or Subgroup

Total

SD

Mean

Total

SD

Mean

1. 2017
2. 2018

1. -1.12 [-2.27, 0.03]
2. -1.12 [-1.22, -1.02]
3. -1.21 [-1.94, -0.48]
4. -1.33 [-1.77, -0.89]
5. -1.13 [-1.23, -1.04]

0.7 92.9 1.7 4.7

21 51 50 30

2.27 0.27 2.28 0.93

8.86 4.38 8.85 3.92

21 51 50 30

1.42 0.24 1.32 0.81

Shi YF 2017 Zhou G 2018 Chen E 2020 Zhang TT 2021

7.74 3.26 7.64 2.59

1. 2020
2. 2021

100.0

152

Total (95% CI) Heterogeneity: Tau2 = 0.00; Chi2 = 0.87, df = 3 (P = 0.83); I2 = 0% Test for overall effect: Z = 23.20 (P < 0.00001) -100

152

-50 0 50 100

Favours [experimental] Favours [control]

Figure 7: Forest plot of fibrinogen.

Odds Ratio M-H, Random, 95% CI M-H, Random, 95% CI

Experimental Control Odds Ratio

Weight (%)

Study or Subgroup

Year

Total

Total

Events

Events

2017 2017 2020

1.54 [0.42, 5.72] Not estimable 0.65 [0.10, 4.09] 0.47 [0.08, 2.75] 0.62 [0.15, 2.45]

33.8 17.1 18.7 30.3 100.0

73 49 46 39 30

73 49 46 39 30

4 0

Wang LM 2017 Yang T 2017 Wu Y 2020 Zhang DN 2020 Zhang TT 2021

6 0 2 2 4

1. 3
2. 4 6

1. 2020
2. 2021

Total (95% CI) Total events Heterogeneity: Tau2 = 0.00; Chi2 = 1.50, df = 3 (P = 0.68); I2 = 0% Test for overall effect: Z = 0.55 (P = 0.58)

0.81 [0.38, 1.73]

237

237

17

14

0.01 0.1 1 10 100

Favours [experimental] Favours [control]

Figure 8: Forest plot of adverse reaction analysis.

cardiovascular system, nervous system, respiratory system and other fields and has become renowned for its curative effects. It has a good effect on the treatment of ischemic stroke, subarachnoid hemorrhage, senile dementia, vascular dementia, ischemic heart disease, hyperlipidemia, asthma, chronic pulmonary heart disease, sudden deafness, diabetic peripheral neuropathy, cancer, and many other diseases [38].

However, with the wider application of GLP in clinical practice, there have been more and more reports on the occurrence of adverse reactions, and there is a lack of evidence-based medicine to evaluate GLP’s efficacy and safety. MA provides a comprehensive and complete reference for the use of clinical GLP. is paper systematically analyzed the experimental data of 13 included GLPs in the treatment of ischemic stroke. Our MA results show that NIHSS results were as follows: WMD −3.89, 95% CI: [−4.22, −3.56], I2 19%, and P< 0.00001; BI results were as follows: WMD 11.30, 95% CI: [9.83, 12.77], I2 7%, and P<0.00001; clinical effective rate results were as follows: WMD 3.79, 95% CI: [2.49, 5.78], I2 0%, and P< 0.00001; plasma viscosity results were as follows: WMD −0.16, 95% CI: [−0.20, −0.12], I2 40%, and P< 0.00001; fibrinogen results were as follows: WMD −1.13, 95% CI: [−1.23, −1.04], I2 0%, and P <0.00001; and adverse reaction results were as follows: WMD 0.81, 95% CI: [0.38, 1.73], I2 0%, and P 0.58, RR<1.

In all cases, we found that the combined effect size was statistically significant. In this study, clinical therapeutic effect, NIHSS, and BI were used as the main indicators. According to the results of our MA, GLP has a positive effect on the treatment of ischemic stroke, and it has a significant improvement effect on the neurological function and the ability to carry on daily living for patients with ischemic stroke. Using hemorheological indices (plasma viscosity and fibrinogen) as secondary measures, our MA suggests that GLP can change hemorheological indices related to ischemic stroke. Some studies have shown that fibrinogen is an important factor that affects the occurrence of stroke, and researchers speculate that increasedfibrinogencontentisapredictorfortheoccurrenceof ischemic stroke [39]. Other studies have shown that fibrinogen can promote platelet aggregation [40]. erefore, we speculate that GLP can aid ischemic stroke patients by improving plasma viscosity and reducing the level of fibrinogen.

However, considering that the test results of hemorheology indices are not necessarily positively correlated with clinical symptoms and conditions, such test results can only provide a reference for clinical treatment.

In the included literature, there were 14 adverse events in the observation groups and 17 in the control groups. e proportion of the number of adverse events in the observation group and the control group was similar, and most of the adverse symptoms disappeared after the end of treatment without the need for special treatment, indicating that the use of GLP did not cause serious adverse reactions. Ginkgo acid is one of the main toxic components in Ginkgo biloba. At present, the methods of Ginkgo biloba deacidification include microwave-assisted extraction, organic solvent extraction, resin extraction, ultrasound-assisted extraction, and supercritical carbon dioxide extraction [41].

Based on clinical safety considerations, the content of ginkgo phenolic acid has become an important control index in the quality standard of ginkgo drug semifinished products as well [42]. With the growing use of Ginkgo biloba, we may expect that its technology will continue to progress, and its quality control standards may become more and more strict. In addition, according to current studies, the occurrence of bleeding caused by GLP is related to the combination of other medications, such as the combination of anticoagulant drugs [9, 43]. is bleeding may also be related to the presence of ginkgolide B, but its specific content in Ginkgo biloba is unknown and remains to be studied. erefore, it may be prudent not to use GLP in combination with anticoagulants such as aspirin and warfarin and to control the dosage strictly within a reasonable range [44].

4.1.ResearchLimitations. is study provides a reference for clinical practice but also has some limitations. First, the quality of the included articles was not a consideration, the number of articles was small, and the overall sample size was also small. Second, of the 13 included articles, some may have used the wrong randomization method, while others did not. Some of them used a random number method, but none of the articles mentioned the implementation of a blind method. ird, all the included experiments were not registered for clinical trials, which could affect the study results to a certain extent, and most of the included experiments

lacked safety evaluation schemes. Finally, different medications and courses of treatment in basic treatment could have led to bias in results, which can affect the reliability of the conclusions from our MA.

is review strengthens the evidence that GLP has a good therapeutic effect on patients with ischemic stroke. ere are some limitations in our current study, but clinical trials are expected to improve the level of evidence even more through more rigorous experimental design, more comprehensive indicators, and large-sample and high-quality RCTs.